

Cybin Announces Launch of EMBARK Psychedelic Facilitator Training Program

10.28.21

TORONTO,

CANADA

-

October 28,

2021

-

[Cybin](#)

Inc.

(NEO:CYBN)

(NYSE

American:CYBN)

("Cybin")

or

the

"Company"),

a

biotechnology

company

focused

on

progressing

psychedelic

announced
the
launch
of
the
EMBARK
Psychedelic
Facilitator
Training
Program.

Led
by
a
team
of
esteemed
faculty,
the
program
offers
psychedelic
clinical
trial
facilitators
the
foundational
training
needed
to
provide
skillful
and
ethical
care
to
participants
receiving
psychedelic
treatment.

emphasis
on
experiential
learning,
the
training
will
kick
off
with
an
in-
person
training
retreat
at
the
Whidbey
Institute,
a
home
for
transformational
learning
in
Washington
state.
The
training
includes
an
experiential
training
component,
in
addition
to
the
core

practice
sessions
on
the
EMBARK
model.
This
fall
cohort
of
EMBARK
facilitators
is
a
collaborative
project
with
the
University
of
Washington,
and
these
facilitators
are
preparing
for
the
first
clinical
trial
exploring
the
potential
of
psilocybin-
assisted
psychotherapy
to

workers
experiencing
COVID-
related
distress.
This
clinical
trial,
co-
sponsored
by
Cybin,
will
aim
to
treat
symptoms
of
depression,
anxiety,
burnout
and
post-
traumatic
stress
among
frontline
doctors,
nurses,
and
healthcare
professionals.
The
study's
Primary
Investigator,
Dr.
Anthony
Back,

Morgan,
RN,
MSW,
have
contributed
to
an
adapted
version
of
the
EMBARK
therapy
manual
to
address
the
unique
needs
of
healthcare
workers
affected
by
the
pandemic.
The
study
will
be
hosted
in
Seattle,
a
city
hit
hard
with
an

outbreak.
The
training
curriculum
is
based
on
EMBARK,
a
ground-
breaking
psychotherapy
model
that
integrates
leading
clinical
approaches
to
promote
supportive
healing
with
psychedelic
medicine.
EMBARK's
creators,
Bill
Brennan,
PhD
(cand.)
and
Alex
Belser,
PhD,
Cybin's
Chief
Clinical
Officer,

process
evidence
in
psychedelic
clinical
practice
and
the
experience
of
senior
teachers
and
supervisors.
EMBARK
is
a
transdiagnostic
model
that
is
adaptable
to
different
clinical
indications
and
challenges
including
depression,
alcohol
use
disorder,
and
anxiety.
“We’re
excited
to
host

When we first created EMBARK, we canvassed twenty different psychedelic-assisted psychotherapies.

We found that some therapies left out important aspects, like people's spiritual experiences, somatic experiences, or human relationships.

Patients were telling us that these experiences were central

healing,
but
many
therapies
seemed
to
be
missing
critical
pieces.
To
address
this
challenge,
we
developed
EMBARK,
which
provides
an
open
architecture
to
support
the
varieties
of
psychedelic
experience
within
a
coherent
therapeutic
framework.
This
is
a
patient-
centered

the
whole
person,”
said
Dr.
Alex
Belser,
EMBARK’s
co-
author
and
Cybin’s
Chief
Clinical
Officer.

EMBARK’s
six
clinical
domains
(Existential-
Spiritual,
Mindfulness,
Body
Aware,
Affective-
Cognitive,
Relational,
Keeping
Momentum)
represent
the
broad
spectrum
of
ways
in
which
therapeutic
benefits

in
psychedelic
treatment
and
the
equally
broad
training
needed
to
prepare
therapists
to
support
them
all.

Training
in
EMBARK
prepares
facilitators
to
work
within
all
of
these
domains,
while
inviting
facilitators
to
bring
in
their
own
therapeutic
training
and

a
flexible,
yet
structured
way.
The
EMBARK
curriculum
additionally
emphasizes
trauma-
informed,
culturally
competent,
and
ethically
rigorous
care.

“Psychedelic
medicines
and
the
great
healing
potential
they
hold
have
only
just
begun
to
find
their
place
in
our
culture
and

of
therapeutic
approaches.
EMBARK
represents
an
important
step
forward
in
that
process.
We
designed
it
to
be
uniquely
responsive
to
the
distinctive
and
disruptive
ways
that
these
medicines
heal
people,
while
also
able
to
incorporate
synergistic
aspects
of
other

treatments.
Its
flexible,
six-
domain
structure
allows
us
to
open
the
aperture
on
our
notions
of
healing
and
expand
our
ability
to
help
patients
reach
a
place
of
wellness.
We
offer
EMBARK
in
a
spirit
of
service
and
deep

psychedelic
medicines
and
the
many
avenues
of
healing
they
open
to
us,"
said
Bill
Brennan,
PhD
(cand.),
EMBARK's
co-
creator.

**About
Cybin**

Cybin
is
a
leading
biotechnology
company
focused
on
progressing
[psychedelic
therapeutics](#)
by
utilizing
proprietary
drug
discovery
platforms,

delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

Cautionary Notes and Forward-Looking Statements

Certain statements in this press release constitute forward-looking information.

All statements other than statements of historical fact contained in this press

without
limitation,
statements
regarding
Cybin's
future,
strategy,
plans,
objectives,
goals
and
targets,
and
any
statements
preceded
by,
followed
by
or
that
include
the
words
"believe",
"expect",
"aim",
"intend",
"plan",
"continue",
"will",
"may",
"would",
"anticipate",
"estimate",
"forecast",
"predict",
"project",
"seek",

similar
expressions
or
the
negative
thereof,
are
forward-
looking
statements.
Forward-
looking
statements
in
this
news
release
include
statements
regarding
the
Company's
proprietary
drug
discovery
platforms,
innovative
drug
delivery
systems,
novel
formulation
approaches
and
treatment
regimens
to
potentially
treat

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties,

factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of

19
pandemic
on
the
Company's
operations;
fluctuations
in
general
macroeconomic
conditions;
fluctuations
in
securities
markets;
expectations
regarding
the
size
of
the
psychedelics
market;
the
ability
of
the
Company
to
successfully
achieve
its
business
objectives;
plans
for
growth;
political,
social

uncertainties;
employee
relations;
the
presence
of
laws
and
regulations
that
may
impose
restrictions
in
the
markets
where
the
Company
operates;
and
the
risk
factors
set
out
in
the
Company's
management's
discussion
and
analysis
for
the
period
ended
June
30,

the
Company's
listing
statement
dated
November
9,
2020,
which
are
available
under
the
Company's
profile
on
www.sedar.com
and
with
the
U.S.
Securities
and
Exchange
Commission
on
EDGAR
at
www.sec.gov.
Although
the
forward-
looking
statements
contained
in
this
news
release

upon
what
management
of
the
Company
believes,
or
believed
at
the
time,
to
be
reasonable
assumptions,
the
Company
cannot
assure
shareholders
that
actual
results
will
be
consistent
with
such
forward-
looking
statements,
as
there
may
be
other
factors
that

not
to
be
as
anticipated,
estimated
or
intended.

Readers
should
not
place
undue
reliance
on
the
forward-
looking
statements
and
information
contained
in
this
news
release.

The
Company
assumes
no
obligation
to
update
the
forward-
looking
statements
of
beliefs,

or other factors, should they change, except as required by law.

Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products.

The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not

regarding
psilocybin,
psychedelic
tryptamine,
tryptamine
derivatives
or
other
psychedelic
compounds
or
nutraceutical
products.
The
efficacy
of
such
products
has
not
been
confirmed
by
approved
research.
There
is
no
assurance
that
the
use
of
psilocybin,
psychedelic
tryptamine,
tryptamine
derivatives
or

compounds
or
nutraceuticals
can
diagnose,
treat,
cure
or
prevent
any
disease
or
condition.
Vigorous
scientific
research
and
clinical
trials
are
needed.
Cybin
has
not
conducted
clinical
trials
for
the
use
of
its
proposed
products.
Any
references
to
quality,
consistency,

safety
of
potential
products
do
not
imply
that
Cybin
verified
such
in
clinical
trials
or
that
Cybin
will
complete
such
trials.
If
Cybin
cannot
obtain
the
approvals
or
research
necessary
to
commercialize
its
business,
it
may
have
a
material

on
Cybin's
performance
and
operations.

*Neither
the
Neo
Exchange
Inc.
nor
the
NYSE
American
LLC
stock
exchange
have
approved
or
disapproved
the
contents
of
this
news
release
and
are
not
responsible
for
the
adequacy
and
accuracy
of
the*

Investor

Contacts:

Tim

Regan/Scott

Eckstein

KCSA

Strategic

Communications

Cybin@kcsa.com

Lisa

M.

Wilson

In-

Site

Communications,

Inc.

lwilson@insitecony.com

Media

Contact:

John

Kanakis

Cybin

Inc.

John@cybin.com



5600-100 King St W, Toronto ON M5X 1C9

Investor Contact: ir@cybin.com

General Contact: info@cybin.com

Our Work

[Development Pipeline](#)

[The Science](#)

[Cybin x Kernel](#)

Investors

[Press Releases](#)

[Financials](#)

[Corporate Governance](#)

[Downloads](#)

About Us

[Mission](#)

[Team](#)

[News](#)

[Join Us](#)

[Contact](#)